Oncolytic viruses

Investigational New Drugs

Volumn 17, Issue 4, 1999, Pages 375-386

  Nemunaitis, John ^a,b  

^a University of South Carolina   (United States)

^b BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Lysis; Malignant; Oncolytic; Viruses

Indexed keywords

ONCOLYTIC VIRUS;

CANCER CELL; CYTOLYSIS; FEVER; PAIN; PRIORITY JOURNAL; REVIEW; TUMOR NECROSIS; VIRUS ATTENUATION; VIRUS REPLICATION;

ANIMALS; HUMANS; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; VIRUSES;

EID: 0033507699     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006334404767     Document Type: Review

References (128)

1. Niemialtowski MG, Toka FN, Malicka E Gierynska M, Spohr de Faundez I, Schollenberger A: Controlling orthodox virus infections - 200 years after Jenner's revolutionary immunization. Archivum Immunologiae et Therapiae Experimentalis 44: 373-378, 1996
2. Ellner PD: Smallpox: Gone but not forgotten. Inf 26(5): 283-269, 1998
3. Hansen RM, Libnoch JA: Remission of chronic lymphocytic leukemia after smallpox vaccination. Arch Intern Med 138: 1137-1138, 1978
4. Bousser J, Zittoun R: Remission spontanee prolongee D-une leucemie lymphoide chromique. Nouv Rev Fr Hematol 5: 498-501, 1965
5. Vladimirskaia EB: A case of prolonged spontaneous remission in a patient with chronic lymphocytic leukemia. Probl Gematol Pereliv Krovi 7: 51-54, 1962
6. Weintraub LR: Lymphosarcoma: Remission associated with viral hepatitis. JAMA 24: 1590-1591, 1969
7. Sinkovics JG: Oncolytic viruses and viral oncolysates. Ann Immun Hungaricae 26: 271-290, 1986
8. Dock G: Influence of complicating diseases upon leukaemia. Am J Med Sci 127: 563-592, 1904
9. Bierman HR, Hammon WMcD, Eddie BU, Meyer KF, Shimkin MB: The effect of viruses and bacterial infections on neoplastic diseases. Cancer Res 10(abstr): 203-204, 1950
10. Bluming AZ, Ziegler JL: Regression of Burkitt's lymphoma in association with measles infection. Lancet II: 105-106, 1971
11. Taqi AM, Abdurraham MB, Yabubu AM, Fleming AF: Regression of Hodgkin's disease after measles. Lancet I: 1112, 1981
12. Hernadez A: Observation de un case de enfermedad de Hodgkin, con regresion de los sintomas e infartos ganglionares, post-sarampion. Rev Med Cubana 60: 120-125, 1949
13. Bierman HR, Crile DM, Dod KS: Remissions in leukemia of childhood following acute infectious disease; staphylococcus and streptococcus, varicella, and feline panleukopenia. Cancer 6: 591-605, 1953
14. Pelner L, Fowler GA, Nauts HC: Effects of concurrent infections and their toxins on the course of leukaemia. Acta Med Scand 338(suppl): 1-47, 1958
15. London RE: Multiple myeloma: report of a case showing unusual remission lasting two years following severe hepatitis. Ann Intern Med 43: 191-201, 1955
16. De Pace NG: Ginnecologia 9: 82, 1912
17. Pack GT: Note of the experimental use of rabies vaccine for melanomatosis. Arch Dermatol and Syphilol 62: 694-695, 1950
18. Moore AE: Inhibition of growth of five transplantable mouse tumors by the virus of Russian far east encephalitis. Cancer 4: 375-382, 1951
19. Flanagan AD, Love R, Tesar W: Propagation of Newcastle disease virus in Ehrlich ascites cells in vitro and in vivo. Proc Soc Biol Med 90: 82-86, 1955
20. Prince AM, Ginsberg HS: Immunohistochemical studies on the interaction between Ehrlich ascites tumor cells and Newcastle disease virus. J Exp Med 105: 177-187, 1957
21. Sinkovics J: Studies on the biological characteristics of the Newcastle disease virus (NDV) adapted to the brain of newborn mice. Arch Ges Virusforsch 7: 403-411, 1957
22. Ackermann W, Kurtz H: A new host-virus system. Proc Soc Exp Biol Med 81: 421-423, 1957
23. Cassel WA: Multiplication of influenza virus in Ehrlich ascites carcinoma. Cancer Res 17: 618-622, 1957
24. Southam CM: Present status of oncolytic virus studies. Trans NY Acad Sci 22: 657-673, 1960
25. Asada T: Treatment of human cancer with mumps virus. Cancer 34(16): 1907-1928, 1974
26. Yamanishi E, Takahashi M, Kurimura T, Ueda S, Minekawa Y: Studies on live mumps virus vaccine - III. Evaluation of newly developed live mumps virus vaccine. Biken J 13: 157-161, 1970
27. Moore AE: Carcinolytic viruses. In: Biological Approaches to Cancer Chemotherapy. Harris RJC (ed), New York, Academic Press, pp 365-370, 1961
28. Sinkovics JG: In: Die Grundlagen der Virusforschung. Budapest, Ungarische Akademie der Wissenschaften, pp 98-103, 235-247, 1956
29. Harris JE, Sinkovics JG (eds): The Immunology of Malignant Disease. St. Louis, Mosby, pp 180-182, 464-467, 475-478, 1976
30. Hoster HA, Zanes RP, von Haam E: Studies in Hodgkin's syndrome. Cancer Res 9: 473-480, 1949
31. Lowe SW, Ruley HE: Stabilization of the p53 tumor suppressor is induced by adenovirus 5 E1A and accompanies apoptosis. Genes Dev 7: 535-545, 1993
32. 2/neu oncogene-induced metastasis and repression of metastatic properties by adenovirus 5 E1A gene products. Oncogene 7: 2263-2270, 1992
33. Lorence RM, Rood PA, Kelley KW: Newcastle disease virus as an antineoplastic agent. Introduction of tumor necrosis factor-α and augmentation of its cytotoxicity. J Natl Cancer Inst 80: 1305-1312, 1988
34. Sinkovics JG: Project M27/gm23: Production of human interferon. Research Report, MD Anderson Hospital University of Texas Press, Austin, 332 pp, 1978
35. Sinkovics J, Horvath J: New development in the virus therapy of cancer: A historical review. Intervirol 36: 193-214, 1993
36. Marsch M, Helenius A: Virus entry into animal cells. Adv Virus Res 36: 107-151, 1989
37. Neda H, Wu CH, Wu GY: Chemical modification of an ecotropic murine leukemia virus results in redirection of its target cell specification. J Biol Chem 266: 14143-14146, 1991
38. Russell SJ, Brandenburger A, Fleming CL, Collins MKL, Rommelaere J: Transformation-dependent expression of interleukin genes delivered by a recombinant parvovirus. J Virol 66: 2821-2828, 1992
39. Friedman JM, Babiss LE, Clayton DF, Darnell Jr JE: Cellular promoters incorporated into the adenovirus genome: cell specificity of albumin and immunoglobulin expression. Mol Cell Biol 6: 3791-3797, 1986
40. Peplinski GR, Tsung K, Norton JA: Vaccinia virus for human gene therapy. Cancer Gene Ther 7(3): 575-588, 1998
41. North RJ: Down regulation of the anti-tumor immune response. Adv Cancer Res 45: 1-37, 1985
42. Scherer WF, Syverton JT, Gey GO: Studies on the propagation in vitro of poliomyelitis viruses. IV. Viral multiplication in a stable strain of human malignant epithelial cells (strain HeLa) derived from an epidermoid carcinoma of the cervix. J Exper Med 97: 695-709, 1953
43. Southam CM, Moore AE: Clinical studies of viruses as antineoplastic agents with particular reference to Egypt 101 virus. Cancer 5: 1025-1034, 1952
44. Smith RR, Huebner JR, Rowe WP, Schatten WE, Thomas LB: Studies on the use of viruses in the treatment of carcinoma of the cervix. Cancer 9: 1211-1218, 1956
45. Sinkovics JG: Oncogenes-antioncogenes and virus therapy of cancer. Anticancer Res 9: 1281-1290, 1989
46. Russell SJ: Replication vectors for gene therapy of cancer: Risks, limitations and prospects. Eur J Cancer 30A(8): 1165-1171, 1994
47. Asada T: A new attempt for cancer therapy. Jap Red Cross Med J 16: 9-19, 1963
48. Csatary LK, Eckhardt S, Bukosza I, Czegledy F, Fenyvesi C, Gergely P, Bodey B, Csatary CM: Attenuated veterinary virus vaccine for the treatment of cancer. Cancer Detect Prev 17(6): 619-627, 1993
49. Csatary LK, Gergely P: Virus vaccines for the treatment of cancer. Orv Hetil 131: 2585-2588, 1990
50. Shimizu Y, Hasumi K, Okudaira Y: Immunotherapy of advanced gynecologic cancer patients utilizing mumps virus. Cancer Detect Prev 12: 487-495, 1988
51. Okuno Y, Asada T, Yamanishi K: Studies on the use of mumps virus for treatment of human cancer. Biken J 21: 37-49, 1978
52. Cassel WA, Garrett RE: Newcastle disease virus as an antineoplastic agent. Cancer 18(7): 863-868, 1965
53. Reichard KW, Lorence RM, Cascino CJ: N-myc oncogene enhances the sensitivity of neuroblastoma to killing by Newcastle disease virus. Surg Forum 43: 603-606, 1992
54. Heicappell R, Schirmacher V, Von Hoegen P: Prevention of metastatic spread by postoperative immunotherapy with virally modified autologous tumor cells. I. Parameters for optional therapeutic effects. Int J Cancer 37: 569-577, 1986
55. Von Hoegen P, Weber E, Schirrmacher V: Modification of tumor cells by a low dose of Newcastle disease virus. Augmentation of the tumor-specific T-cell response in the absence of anti-viral response. Eur J Immunol 18: 1159-1166, 1988
56. Schirmacher V, Ahlert T, Heicappell R: Successful application of non-oncogenic virus for antimetastatic cancer immunotherapy. Cancer Rev 5: 19-32, 1986
57. Bar-Eli N, Giloh H, Schlesinger M, Zakay-Rones Z: Preferential cytotoxic effect of Newcastle disease virus on lymphoma cells. Cancer Res Clin Oncol 122: 409-415, 1996
58. Tzadok-David Y, Metzkin-Eizenberg M, Zakay-Rones Z: The effect of a mesogenic and a lentogenic Newcastle disease virus strain of Burkitt lymphoma Daudi cells. Cancer Res Clin Oncol 121: 169-174, 1995
59. Reichard KW, Lorence RM, Cascino CJ, Peeples ME, Walter RJ, Fernando MB, Reyes HM, Greager JA: Newcastle dis-ease virus selectively kills human tumor cells. J Surg Res 52: 448-453, 1992
60. Sinkovics J, Howe CD: Super-infection of tumors with viruses. Experientia 25: 733-734, 1969
61. Cassel WA, Murray DR, Phillips HS: A Phase II study on the post-surgical management of Stage II malignant melanoma with a Newcastle disease virus oncoiysate. Cancer 52(5): 856-860, 1983
62. Cassel WA, Murray DR: A ten-year follow-up on stage II malignant melanoma patients treated post-surgically with Newcastle disease virus oncolysate. Med Oncol Tumor Pharmacother 9: 169-171, 1992
63. Cassell WA, Murray DR: Letter to the Editor. Nat Immun Cell Growth Regul 7: 351-352, 1988
64. Eilber FR, Morton DL, Holmes CE, Sparks FC, Ramming KP: Adjuvant immunotherapy with BCG in treatment of regional-lymph node metastases from malignant melanoma. N Engl J Med 294: 237-240, 1976
65. Gutterman JU, McBride C, Freireich EJ, Mavligit G, Frei E, Hersh EM: Active immunotherapy with BCG for recurrent malignant melanoma. Lancet 1: 1208-1212, 1973
66. Schlag P, Manasterski M, Gerneth T, Hohenberger P, Kueck M, Herfarth C, Liebrich W, Schirrmacher V: Active specific immunotherapy with Newcastle disease virus modified autologous tumor cells following resection of liver metastases in colorectal cancer. First evaluation of clinical response of a Phase II trial. Cancer Immunol Immunother 35: 325-330, 1992
67. Kirschner HH, Anton P, Atzpodien J: Adjuvant treatment of locally advanced renal cancer with autologous virus-modified tumor vaccines. World J Urol 13: 171-173, 1995
68. Haas C, Straus G, Moldenhauer G, lorio RM, Schirrmacher V: Bisopecific antibodies increase T-cell stimulatory capacity in vitro of human autologous virus-modified tumor vaccine. Clin Cancer Res 4: 721-730, 1998
69. Haas C, Schirrmacher V: Immunogenicity increase of autologous tumor cell vaccines by virus infection and attachment of bispecific antibodies. Cancer Immunol Immunother 43: 190-194, 1996
70. Berd D, Mastrangelo MJ: Active immunotherapy of human melanoma exploiting the immunopotentiating effects of cyclophosphamide. Cancer Inv 6: 337-349, 1988
71. Hoover SK, Barrett SK, Turk TMT, Lee T-C, Bear HD: Cyclophsphamide and abrogation of tumor-induced suppressor T-cell activity. Cancer Immunol Immunother 31: 121-127, 1990
72. Freedman RS, Edwards CL, Bowen JM, Lotzova E, Katz R, Lewis E, Atkison N, Carsetti R: Viral oncolysates in patients with advanced ovarian cancer. Gynecol Oncol 29: 337-347, 1988
73. Cassel WA, Garrett RE: Relationship between viral neurotropism and oncolysis. II. Study of Influenza virus. Cancer 20(3): 440-444, 1967
74. Boone CW: Augmented immunogenicity of tumor cell homogenates infected with influenza virus. Recent Results Cancer Res 47: 394-400, 1974
75. loannides CG, Platsoucas CD, Patenia R, Kim YP, Bowen JM, Morris M, Edwards G, Wharton JT, Freedman RS: T-cell functions in ovarian cancer patients treated with viral oncolysates: I. Increased helper activity to immunoglobulins production. Anticancer Res 10: 645-654, 1990
76. Goebel SJ, Johnson GP, Perkus ME: The complete DNA sequence of vaccinia virus. Virol 179: 247-266, 1990
77. Wallack MK, Steplewski Z, Koprowski H, Rosato E, George J, Hulihan B: A new approach in specific, active immunotherapy. Cancer 39: 560-564, 1977
78. Wallack MK, Sivanandham M, Balch CM, Urist MM, Bland KI, Murray D, Robinson WA, Flaherty L, Richards JM, Bartolucci AA, Rosen L: Surgical adjuvant active specific immunotherapy for patients with Stage III melanoma: The final analysis of data from a Phase III randomized double-blind, multicenter vaccinia melanoma oncolysate trial. Am J Coil Surg 187(1): 69-79, 1998
79. Cassel WA, Garrett RE: Relationship between viral neurotropism and oncolysis. I. Study of vaccinia virus. Cancer 20(3): 433-439, 1967
80. Cassell WA, Murray DR, Torbin AH, Olkowski ZL, Moore ME: Viral oncolysate in the management of malignant melanoma. I. Preparation of the oncolysate and measurement of immunologic responses. Cancer 40(2): 672-679, 1977
81. Barnavon Y, Iwaki H, Bash JA, Brettschneider F, Hilsenbeck S, Darnell E, Wallack MK: Treatment of murine hepatic metastases with vaccinia colon oncolysate and IL-2. J Surg Res 45: 523, 1988
82. Barnavon Y, Iwaki H, Bash JA, Wallack MK: Vaccinia colon oncolysate immunotherapy for murine hepatic metastases can be modulated with low-dose interleukin-2. Am Surg 54: 696, 1988
83. Wu KS, Ueda S, Skaue Y: Prevention of syngeneic tumor growth in vaccinia virus-modulated tumor cells. Biken J 24: 153-158, 1981
84. Shimizu Y, Fujiwara H, Ueda S: The augmentation of tumor-specific immunity by virus help. U. Enhanced induction of cytotoxic T-lymphocyte and antibody to tumor antigens by vaccinia virus-reactive helper T-cells. Eur J Immunol 14: 839-843, 1984
85. Wallack MK, Bash JA, Leftheriotis E, Seigler H, Bland K, Wanebo H, Balch C, Bartolucci A: Positive relationship of clinical and serologic responses to vaccinia melanoma oncolysate. Arch Surg 122: 1460-1463, 1987
86. Wallack MK, Michaelides MC: Serologic responses to human melanoma line from patients with melanoma undergoing treatment with vaccinia melanoma oncolysates. Surg 96: 791-799, 1984
87. Wallack MK, Meyer M, Burgoin A: A preliminary trial of vaccinia oncolysates in the treatment of recurrent melanoma with serologic responses to the treatment. J Biol Response Mod 2: 586-596, 1983
88. Wallack MK, McNally KR, Leftheriotis E: A Southeastern Cancer Study Group Phase I/II trial with vaccinia melanoma oncolysates. Cancer 57: 649-655, 1986
89. Wallack MK, Scoggin SD, Sivanandham M: Active specific immunotherapy with vaccinia melanoma oncolysate. Mount Sinai J Med 59(3): 227-233, 1992
90. Scoggin SD, Sivanandham M, Sperry RG, Wallack MK: Active specific adjuvant immunotherapy with vaccinia melanoma oncolysate. Ann Plast Surg 28: 108-109, 1992
91. Stevens JG, Cook ML: Latent herpes simplex virus in spinal ganglia of mice. Science 173(999): 843-845, 1971
92. Palella TD, Silverman L, Schroll CT, Homa FL, Levine M, Kelley WN: Herpes simplex virus-mediated human hypoxanthine-guanine phosphoribosyltransferase gene transfer into neuronal cells. Mol Cell Biol 8(1): 457-460, 1988
93. Geller Al, Breakefield WX: A defective HSV-1 vector expresses Escherichia coli beta-galactosidase in cultured peripheral neurons. Science 241: 1667-1669, 1988
94. Coen DM, Kosz-Vnenchak M, Jacobson JG, Leib DA, Bogard CL, Schaffer PA, Tyler KL, Knipe DM: Thymidine kinase-negative herpes simplex virus mutants establish latency in mouse trigeminal ganglia but do not reactivate. Proc Natl Acad Sci USA 86: 4736-4740, 1989
95. Martuza RL, Malick A, Markert JM, Ruffner KL, Coen DM: Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 252: 854-856, 1991
96. Jamieson AT, Gentry GA, Subak-Sharpe JH: Biochemical studies on the herpes simplex virus-specified deoxypyrimidine kinase activity. J Gen Virol 24(3): 481-492, 1974
97. Field HJ, Wildy P: The pathogenicity of thymidine kinase-deficient mutants of herpes simplex virus in mice. J Hyg (London) 81(2): 267-277, 1978
98. Jia WAG, McDermott M, Goldie J, Cynader M, Tan J, Tufaro F: Selective destruction of gliomas in immunocompetent rats by thymidine kinase-defective herpes simplex virus type 1. J Natl Cancer Inst 86(16): 1209-1215, 1994
99. Mineta T, Rabkin SD, Yazaki T, Hunter WD, Martuza RL: Attenuated multimutated herpes simplex virus-1 for the treatment of malignant gliomas. Nature Med 1(9): 938-943, 1995
100. Toda M, Rabkin SD, Martuza RL: Treatment of human breast cancer in a brain metastatic model by G207, a repllcation-competent multimutated herpes simplex virus 1. Hum Gene Ther 9: 2177-2185, 1998
101. Randazzo B, Kesari Sa, Gesser RM, Alsop D, Ford JC, Brown SM, MacLean A, Graser NW: Treatment of experimental intracranial murine melanoma with a neuroattenuated herpes simplex virus 1 mutant. Virol 211: 94-101, 1995
102. Yazaki T, Manz HJ, Radbin SD, Martuza RL: Treatment of human malignant meningiomas by G207, a replication-competent multimutated herpes simplex virus 1. Cancer Res 55: 4752-4756, 1995
103. Toda M, Martuza RL, Kojima H, Rabkin SD: In situ cancer vaccination: An IL-12 defective vector/replication-competent herpes simplex virus combination induces local and systemic antitumor activity. J Immunol 160: 4457-4464, 1998
104. Brandt CD, Kim HW, Vargosko AJ, Jeffries BC, Arrrobio JO, Rindge B, Parrott RH, Chanock RM: Infections in 18,000 infants and children in controlled study of respiration tract disease. Adenovirus pathogenicity in relation to serologic type and illness syndrome. Am J Epidem 90: 484-500, 1969
105. Hierholzer JC: Adenoviruses in the immunocompromised host. Clin Microbiol Rev 5: 262-274, 1992
106. Takafuji ET: Simultaneous administration of live, entericcoated adenovirus types 4, 7, and 21 vaccines: Safety and immunogenicity. J Infect Disease 140: 48-53, 1979
107. Green M, Wold WS, Mackey JK, Rigden P: Analysis of human tonsil and cancer DNAs and RNAs for DNA sequences in group C (serotypes 1, 2, 5 and 6) human adenoviruses. Proc Natl Acad Sci USA 76(12): 6606-6610, 1979
108. Lesoon-Wood LA, Kim WH, Kleinman HK: Systemic gene therapy with p53 reduces growth and metastases of a malignant human breast cancer in nude mice. Human Gene Ther 6: 395-405, 1995
109. Zhang W, Alemany R, Wang J: Safety evaluation of AdCMV-p53 in vitro and in vivo. Human Gene Ther 6: 155-164, 1995
110. Nielsen LL, Dell J, Maxwell E: Efficacy of p53 adenovirus-mediated gene therapy against human breast cancer xenografts. Cancer Gene Ther 4(2): 129-138, 1997
111. Simon RH, Engelhardt JF, Yang Y: Adenovirus-mediated transfer of the CFRT gene to lung of non-human primates: Toxicity study. Human Gene Ther 4: 771-780, 1993
112. Xu M, Kumar D, Srinivas S: Parenteral gene therapy with p53 inhibits human breast tumor in vivo through a bystander mechanism without evidence of toxicity. Human Gene Ther 8: 177-185, 1998
113. Gomez-Foix AM, Coats WS, Baque S: Adenovirus-mediated transfer of the muscle glycogen phosphorylate gene into hepatocytes confers altered regulation of glycogen. J Biol Chem 267: 25129-25134, 1992
114. Le Gal La Salle G, Robert JJ, Bernard S: An adenovirus vector for gene transfer into neurons and glia in the brain. Science 259: 988-990, 1993
115. Tursz T, Le Cesne A, Baldeyrou P: Phase I study of a recombinant adenovirus-mediated gene transfer in lung cancer patients. J Natl Cancer Inst 88: 1857-1863, 1996
116. Harvey BG, Worgall S, Ramirez M: Host responses to intradermal administration of a first generation replication deficient adenovirus vector to normal individuals. Am Soc Gene Ther (Abstr 167) 43a, 1998
117. Lechner MS, Mack DH, Finicle AB, Crook T, Vousden KH, Laimins LA: Human papilloma virus E6 proteins bind p53 in vivo and abrogate p53-mediated repression oftranscription. EMBOJ 11: 3045-3052, 1992
118. Gannon JV, Lane DP: p53 and DNA polymerase alpha compete for binding to SV40 T antigen. Nature 329: 456-458, 1987
119. Barker DD, Berk AJ.: Adenovirus proteins from both E1B reading frames are required for transformation of rodent cells by viral infection and DNA transfection. Virol 156: 107-121, 1987
120. Bischoff JR, Kirn DH, Williams A, Heise C, Horn S, Muna M, Ng L, Nye JA, Sampson-Johannes A, Fattaey A, McCormick F: An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 274: 373-376, 1996
121. Heise C, Sampson-Johannes A, Williams A, McCormick F, Von Hoff DD, Kirn DH: ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med 3(6): 639-645, 1997
122. Kenney S, Pagano JS: Viruses as oncolytic agents: A new age for "therapeutic" viruses? J Nat Cancer Inst 86: 1185-1186, 1994
123. Yang Y, Nunes FA, Berenscsi K, Furth EE, Gonczol E, Wilson JM: Cellular immunity to viral antigens limits El-deleted adenoviruses for gene therapy. Proc Natl Acad Sci USA 91(10): 4407-4411, 1994
124. Nemunaitis J: Phase II trials of intratumoral ONYX-015, and E1B 55-kDa gene-deleted adenovirus alone and in combination with Cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Cancer Gene Ther 5(6): S26 (Abstr 0-8), 1998
125. Kirn D, Nemunaitis J, Ganly M: A Phase II trial of intratumor injection with an E1B-deleted adenovirus, ONYX-015, in patients with recurrent refractory head and neck cancer. Proc ASCO 1: 391a (abstr 1509), 1998
126. Bensadoun RJ, Franquin JC, Benezery K, Ciais G, Aardieu C, Dejou J: Low energy He/Ne laser in the prevention of radiation induced mucositis: A multicenter Phase III double blind study of patients with head and neck cancer. Proc ASCO 18: 390a (abstr 1509), 1999
127. Bergsland E, Mani S, Kirn D: Intratumoral injection of ONYX-015 for gastrointestinal tumors metastatic to the liver: A Phase I trial. Proc ASCO 17: 211a (abstr 814), 1998
128. Mulvihill SJ, Warren RS, Fell S: A Phase I trial of intratumoral injection with and E1B-attenuated adenovirus, ONYX-015, into unresectable carcinomas of the exocrine pancreas. Proc ASCO 17: 211a (abstr 815), 1998